NiKang Advances CDK2 Degrader with Key Milestone in Cancer Treatment Trial
WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader, NKT3964, by completing the dosing of the first patient cohort in a …
NiKang Advances CDK2 Degrader with Key Milestone in Cancer Treatment Trial Read More